MERK.JKライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (26 4月 2024 @ 17:34):

Stats
本日の出来高	27 200.00
平均出来高	54 881.00
時価総額	1 792.00B
EPS	IDR87.11 ( 2023-09-30 )
次の収益日	( IDR0 ) 2024-05-29
Last Dividend	IDR0 ( N/A )
Next Dividend	IDR0 ( N/A )
P/E	10.05
ATR14	IDR9.20 (0.23%)

PT Merck Tbk 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

PT Merck Tbk 財務諸表

Annual	2023
収益:	IDR961.43B
総利益:	IDR391.73B (40.74 %)
EPS:	IDR397.86

FY	2023
収益:	IDR961.43B
総利益:	IDR391.73B (40.74 %)
EPS:	IDR397.86

FY	2022
収益:	IDR1 124.60B
総利益:	IDR427.59B (38.02 %)
EPS:	IDR401.42

FY	2021
収益:	IDR1 064.39B
総利益:	IDR398.68B (37.46 %)
EPS:	IDR293.89

Financial Reports:

No articles found.

PT Merck Tbk

PT Merck Tbk manufactures and sells pharmaceutical products in Indonesia. It operates through three segments: Biopharma, Consumer Health, and Others. It offers health care products in the areas of cardiovascular, metabolic, oncology, endocrinology, fertility, and neurodegenerative diseases, as well as general medicines. The company also engages in discovering, developing, manufacturing, and marketing pharmaceutical and biological prescription medicines to treat colorectal cancer, head and neck cancer, multiple sclerosis, infertility, growth hormone disorders, and diabetes, as well as thyroid disorders comprising hyperthyroidism and hypothyroidism. In addition, it leases and manages properties. The company was formerly known as PT Merck Indonesia Tbk and changed its name to PT Merck Tbk in June 2002. The company was founded in 1970 and is headquartered in East Jakarta, Indonesia. PT Merck Tbk is a subsidiary of Merck Holding GmbH.